Moreover, it has been reported that MSH6 and PMS2 mutation carriers can benefit more from colonoscopy surveillance since MMR-DCF are both less common and less likely to progress along the adenoma–carcinoma sequence [77]. This evidence concerns the gene PMS2 and adenoma.